Data Insights

LP-184 by Lantern Pharma for Bladder Cancer: Likelihood of Approval

LP-184 is under clinical development by Lantern Pharma and currently in Phase I for Bladder Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - LP-184 in Bladder Cancer

Data Insights

LP-184 by Lantern Pharma for Colorectal Cancer: Likelihood of Approval

LP-184 is under clinical development by Lantern Pharma and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - LP-184 in Colorectal Cancer

Data Insights

LP-184 by Lantern Pharma for Prostate Cancer: Likelihood of Approval

LP-184 is under clinical development by Lantern Pharma and currently in Phase I for Prostate Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - LP-184 in Prostate Cancer

Data Insights

LP-184 by Lantern Pharma for Ovarian Cancer: Likelihood of Approval

LP-184 is under clinical development by Lantern Pharma and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - LP-184 in Ovarian Cancer

Data Insights

LP-184 by Lantern Pharma for Lung Cancer: Likelihood of Approval

LP-184 is under clinical development by Lantern Pharma and currently in Phase I for Lung Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - LP-184 in Lung Cancer

Data Insights

Dimesna by Lantern Pharma for Non-Small Cell Lung Cancer: Likelihood of Approval

Dimesna is under clinical development by Lantern Pharma and currently in Phase II for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Dimesna in Non-Small Cell Lung Cancer

Data Insights

LP-184 by Lantern Pharma for Pancreatic Cancer: Likelihood of Approval

LP-184 is under clinical development by Lantern Pharma and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - LP-184 in Pancreatic Cancer

Data Insights

LP-184 by Lantern Pharma for Pancreatic Cancer: Likelihood of Approval

LP-184 is under clinical development by Lantern Pharma and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase...

Data Insights

LP-284 by Lantern Pharma for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

LP-284 is under clinical development by Lantern Pharma and currently in Phase I for Refractory Chronic Lymphocytic Leukemia (CLL). According...

Likelihood of Approval and Phase Transition Success Rate Model - LP-284 in Refractory Chronic Lymphocytic Leukemia (CLL)

Data Insights

LP-284 by Lantern Pharma for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

LP-284 is under clinical development by Lantern Pharma and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL). According...

Likelihood of Approval and Phase Transition Success Rate Model - LP-284 in Relapsed Chronic Lymphocytic Leukemia (CLL)

Data Insights

LP-284 by Lantern Pharma for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval

LP-284 is under clinical development by Lantern Pharma and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - LP-284 in B-Cell Non-Hodgkin Lymphoma

Data Insights

LP-284 by Lantern Pharma for Mantle Cell Lymphoma: Likelihood of Approval

LP-284 is under clinical development by Lantern Pharma and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - LP-284 in Mantle Cell Lymphoma

Data Insights

LP-284 by Lantern Pharma for Solid Tumor: Likelihood of Approval

LP-284 is under clinical development by Lantern Pharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - LP-284 in Solid Tumor

Data Insights

LP-284 by Lantern Pharma for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

LP-284 is under clinical development by Lantern Pharma and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - LP-284 in Diffuse Large B-Cell Lymphoma

Data Insights

LP-184 by Lantern Pharma for Liver Cancer: Likelihood of Approval

LP-184 is under clinical development by Lantern Pharma and currently in Phase I for Liver Cancer. According to GlobalData, Phase...

Data Insights

Dimesna by Lantern Pharma for Lung Adenocarcinoma: Likelihood of Approval

Dimesna is under clinical development by Lantern Pharma and currently in Phase II for Lung Adenocarcinoma. According to GlobalData, Phase...

Data Insights

LP-184 by Lantern Pharma for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

LP-184 is under clinical development by Lantern Pharma and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to...

Data Insights

LP-184 by Lantern Pharma for Non-Small Cell Lung Cancer: Likelihood of Approval

LP-184 is under clinical development by Lantern Pharma and currently in Phase I for Non-Small Cell Lung Cancer. According to...

Data Insights

LP-184 by Lantern Pharma for Glioblastoma Multiforme (GBM): Likelihood of Approval

LP-184 is under clinical development by Lantern Pharma and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData,...